 |
2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate |
|---|---|
| Trade Name | Atiprimod |
| Orphan Indication | Mulitple myeloma and associated bone resorption |
| USA Market Approval | USA |
| USA Designation Date | 2003-12-02 00:00:00 |
| Sponsor | Callisto Pharmaceuticals, Inc.;2 Executive Drive, Suite 450;Somerset, New Jersey, 08873 |
